Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication

Direct-acting antivirals (DAAs) therapy is associated with fibrosis regression in patients with hepatitis C virus liver cirrhosis.

Aim. To study the dynamic of liver fibrosis in cirrhotic patients with a DAAs-induced sustained virological response (SVR).

Materials and methods. The retrospective cohort study included 80 cirrhotic patients (male — 43%, median age 54 years). Liver stiffness (LS) was measured by transient elastography before treatment and after SVR. Patients with LS improvement ≥30% were included in group 1, other patients — in group 2. Clinical, laboratory and instrumental parameters were assessed. Independent risk factors for the absence of LS improvement ≥30% were determined by binary logistic regression with the definition of odds ration (OR) and 95% confidence interval (CI).

Results. LS reduced from 21.35 (15.2; 27.7) to 13.5 [10.1; 20.0] kPa (p < 0.001), the median reduction was 5.1 [2.6; 11.0] kPa. Regression of fibrosis from F4 to F2 and F3 stages was observed in 16 (20%) and 19 (24%) of cases, respectively. Overall, 36 patients were included in group 1, 44 patients — in group 2. Platelet counts increased in group 1 compared to group 2 by 24.5% vs 5.2% (p = 0.014), a disappearance or reducing the size of esophageal varices were observed in 72% vs. 35% of cases (p = 0.035). Significant differences in ALT, AST, albumin, prothrombin time dynamics were not observed. Baseline albumin level ≤35 g/l is an independent risk factor for the absence of significant improvement of LS: OR 6.7 (95% CI 1.7–25.9, p = 0.006).

Conclusion. SVR leads to fibrosis regression to F2-F3 stages in 44% of patients. Baseline albumin level ≤35 g/l is an independent risk factor for the absence of significant improvement of LS.

1. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529–38. https://doi.org/10.1016/j.jhep.2006.05.2013 PMID: 16879891

2. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999; 131(3): 174–81. https://doi.org/10.7326/0003-4819-131-3-199908030-00003 PMID: 10428733

3. Stukova H.Yu., Kucheryavyi Yu.A., Maevskaya E.A., Maev I.V. Otsenka riska razvitiya oslozhnenii tsirroza pecheni razlichnoi ehtiologii pri ispol’zovanii ul’trazvukovoi ehlastografii pecheni. [Ultrasound elastography of the liver for assessing the risk of complications of its cirrhosis of different etiologies]. Therapeutic archive. 2017; 89(2): 38–44 (in Russian). https://doi.org/10.17116/terarkh201789238-44.

4. Calvaruso V., Di Marco V., Ferraro D., et al. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon. 2013; 13(5): e7176. https://doi.org/10.5812/hepatmon.7176 PMID: 23967020

5. Stasi C., Arena U., Zignego A.L., et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis. 2013; 45(10): 840–3. https://doi.org/10.1016/j.dld.2013.03.023 PMID: 23660078

6. Wang J.-H., Changchien C.-S., Hung C.-H., et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010 May; 25(5): 964–9. https://doi.org/10.1111/j.1440-1746.2009.06194.x PMID: 20546451

7. D’Ambrosio R., Aghemo A., Fraquelli M., et al. The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013 Aug; 59(2): 251–6. https://doi.org/10.1016/j.jhep.2013.03.013 PMID: 23528378

8. Pons M., Santos B., Simon-Talero M., et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol. 2017; 10(8): 619–29. https://doi.org/10.1177/1756283x17715198 PMID: 28835776

9. Knop V., Hoppe D., Welzel T., et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016; 23(12): 994–1002. https://doi.org/10.1111/jvh.12578 PMID: 27500382

10. Pavlov Ch.S., Glushenkov D.V., Ivashkin V.T. Sovremennye v mozhnosti ehlastometrii, fibro- i akti-testa v diagnostike fibroza pecheni. [Modern potentials of elastometry, fibro-and acti-test in diagnostics of liver fibrosis]. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008; 18(4): 43–52 (In Russian).

11. Afdhal N.H., Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99 (6): 1160–74. https://doi.org/10.1111/j.1572-0241.2004.30110.x PMID: 15180741

12. Gomez-Dominguez E., Mendoza J., Rubio S., et al. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther. 2006; 24(3): 513–8. https://doi.org/10.1111/j.1365-2036.2006.02999.x PMID: 16886917

13. Lemoine M., Katsahian S., Ziol M., et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcoholrelated cirrhosis. Aliment Pharmacol Ther. 2008; 28(9): 1102–11. https://doi.org/10.1111/j.1365-2036.2008.03825.x PMID: 18691352

14. Robic M.A., Procopet B., Métivier S., et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011; 55(5): 1017–24. https://doi.org/10.1016/j.jhep.2011.01.051 PMID: 21354450

15. European Association for the Study of the Liver. EASL recommendation on treatment of hepatitis C 2018. J Hepatol. 2018; 69(2): 461–511. https://doi.org/10.1016/j.jhep.2018.03.026 PMID: 29650333

16. Soehendra N., Binmoeller K.F., Seifert H., Schreiber H.W. Therapeutic Endoscopy. Color Atlas of Operative Techniques for the Gastrointestinal Tract. Stuttgart — New York: Thieme; 2005: 74.

17. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8): 646–9. https://doi.org/10.1002/bjs.1800600817 PMID: 4541913

18. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2): 464–70. https://doi.org/10.1053/jhep.2001.22172 PMID: 11172350

19. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48(5): 835-47. https://doi.org/10.1016/j.jhep.2008.02.008 PMID: 18334275

20. D’Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44(1): 217–31. https://doi.org/10.1016/j.jhep.2005.10.013 PMID: 16298014

21. Sporea I., Lupusoru R., Mare R., et al. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment. J Gastrointestin Liver Dis. 2017; 26(2): 145–50. https://doi.org/10.15403/jgld.2014.1121.262.dyn PMID: 28617884

22. Morozov V.G., Frolov A.V., Topornina L.M., et al. Ehffektivnost’ i bezopasnost’ protivovirusnoĬ terapii Paritaprevir/ritonavir + Ombitasvir + Dasabuvir + Ribavirin u bol’nykh tsirrozom pecheni v iskhode khronicheskogo gepatita S. [Efficacy and safety of antiviral therapy with Paritaprevir/ritonavir + Ombitasvir + Dasabuvir + Ribavirin in patients with liver cirrhosis associated with chronic hepatitis C]. Infectious diseases. 2016; 14(4): 37–43 (In Russian). https://doi.org/10.20953/1729-9225-2016-4-37-43

23. Singh S., Facciorusso A., Loomba R., Falck-Ytter Y.T. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018; 16(1): 27–38. https://doi.org/10.1016/j.cgh.2017.04.038 PMID: 28479504

24. Facciorusso A., Del Prete V., Turco A., et al. Long-term liver s ness assessment in HCV patients undergoing antiviral therapy: results from a 5-year cohort study. J Gastroenterol Hepatol. 2018; 33(4): 942–9. https://doi.org/10.1111/jgh.14008 PMID: 28976021

25. Puente Á., Cabezas J., López Arias M.J., et al. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Rev Esp Enferm Dig. 2017; 109(1): 17–25. https://doi.org/10.17235/reed.2016.4235/2016 PMID: 27990835

26. Mandorfer M., Kozbial K., Schwabl P., et al. Sustained virologic response to interferon free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016; 65(4): 692–9. https://doi.org/10.1016/j.jhep.2016.05.027 PMID: 27242316